Modelling the Interplay Between Neuron-Glia Cell Dysfunction and Glial Therapy in Autism Spectrum Disorder.

This review looks at how brain cells called glial cells might play a role in autism. These cells work alongside neurons (nerve cells) in the brain. When glial cells don't work properly or become overactive due to inflammation, they may affect brain connections and contribute to autism symptoms. Researchers found increased glial cell activity in certain brain areas of autistic people.

The review suggests new treatment approaches that target these glial cells, including cell replacement therapies and medications.

This 2023 review explores the emerging understanding of neuron-glia cell interactions in autism spectrum disorder (ASD). The authors propose that disrupted communication between neurons and glial cells, particularly microglia dysfunction, may be a significant factor in ASD pathophysiology. The review highlights evidence of microglial activation in brain regions including the cerebellum, white matter, and cortical areas of autistic individuals. Under inflammatory conditions, reactive glial cells may contribute to synaptic dysfunction and autism-related behaviors.

The review discusses potential therapeutic approaches targeting glial dysfunction, including cell replacement therapy, glial progenitor cell-based treatments, and medications to inhibit microglial activation. This represents a shift toward understanding ASD through the lens of neuron-glia interactions rather than focusing solely on neuronal dysfunction.

The research suggests neuron-glia dysfunction as a potential therapeutic target in ASD. However, the proposed treatments (cell replacement, glial progenitor therapy, microglial inhibition) remain experimental. Clinical translation requires significant additional research to establish safety, efficacy, and appropriate patient selection criteria.

This is a narrative review without systematic methodology reported. No sample size or specific study selection criteria provided. The evidence synthesis appears descriptive rather than systematic, limiting the strength of conclusions about neuron-glia interactions in ASD.

Autism spectrum disorder (ASD) is a complicated, interpersonally defined, static condition of the underdeveloped brain. Although the aetiology of autism remains unclear, disturbance of neuronglia interactions has lately been proposed as a significant event in the pathophysiology of ASD. In recent years, the contribution of glial cells to autism has been overlooked. In addition to neurons, glial cells play an essential role in mental activities, and a new strategy that emphasises neuron-glia interactions should be applied.

Disturbance of neuron-glia connections has lately been proposed as a significant event in the pathophysiology of ASD because aberrant neuronal network formation and dysfunctional neurotransmission are fundamental to the pathology of the condition. In ASD, neuron and glial cell number changes cause brain circuits to malfunction and impact behaviour. A study revealed that reactive glial cells result in the loss of synaptic functioning and induce autism under inflammatory conditions. Recent discoveries also suggest that dysfunction or changes in the ability of microglia to carry out physiological and defensive functions (such as failure in synaptic elimination or aberrant microglial activation) may be crucial for developing brain diseases, especially autism.

The cerebellum, white matter, and cortical regions of autistic patients showed significant microglial activation. Reactive glial cells result in the loss of synaptic functioning and induce autism under inflammatory conditions. Replacement of defective glial cells (Cell-replacement treatment), glial progenitor cell-based therapy, and medication therapy (inhibition of microglia activation) are all utilised to treat glial dysfunction. This review discusses the role of glial cells in ASD and the various potential approaches to treating glial cell dysfunction.